NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis $0.41 +0.00 (+1.04%) Closing price 04:00 PM EasternExtended Trading$0.40 -0.01 (-3.00%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearside Biomedical Stock (NASDAQ:CLSD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clearside Biomedical alerts:Sign Up Key Stats Today's Range$0.40▼$0.4350-Day Range$0.34▼$0.8852-Week Range$0.29▼$1.65Volume364,782 shsAverage Volume1.85 million shsMarket Capitalization$31.97 millionP/E RatioN/ADividend YieldN/APrice Target$4.20Consensus RatingHold Company Overview Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Read More Clearside Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCLSD MarketRank™: Clearside Biomedical scored higher than 45% of companies evaluated by MarketBeat, and ranked 633rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingClearside Biomedical has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Clearside Biomedical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 1,117.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.70% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 1,117.71%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentClearside Biomedical has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.Search Interest9 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows3 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Stock News HeadlinesClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Hold" by AnalystsAugust 12, 2025 | americanbankingnews.comClearside Biomedical stock soars after Health Canada approves XIPEREJuly 25, 2025 | in.investing.comCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 22 at 2:00 AM | Investors Alley (Ad)Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal DeliveryJuly 25, 2025 | msn.comClearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in CanadaJuly 23, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Clearside Biomedical (CLSD)July 20, 2025 | msn.comClearside Biomedical Insider Trading Activity | NASDAQ:CLSD | BenzingaJuly 18, 2025 | benzinga.comChardan Capital Downgrades Clearside Biomedical (CLSD)July 18, 2025 | msn.comSee More Headlines CLSD Stock Analysis - Frequently Asked Questions How have CLSD shares performed this year? Clearside Biomedical's stock was trading at $0.95 on January 1st, 2025. Since then, CLSD shares have decreased by 57.1% and is now trading at $0.4072. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its earnings results on Friday, August, 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm earned $0.49 million during the quarter, compared to analyst estimates of $0.50 million. When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Top institutional shareholders of Clearside Biomedical include Bridgeway Capital Management LLC (0.26%). Insiders that own company stock include Bradford T Whitmore, George M Lasezkay, Charles A Deignan, Thomas Ciulla, Ngai Hang Victor Chong and Benjamin R Yerxa. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ). Company Calendar Last Earnings8/08/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLSD CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year Founded2011Price Target and Rating Average Price Target for Clearside Biomedical$4.20 High Price Target$6.00 Low Price Target$2.00 Potential Upside/Downside+900.0%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.35 million Net Margins-665.19% Pretax Margin-648.06% Return on EquityN/A Return on Assets-124.15% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual Sales$4.17 million Price / Sales7.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.62) per share Price / Book-0.68Miscellaneous Outstanding Shares78,510,000Free Float73,250,000Market Cap$32.97 million OptionableOptionable Beta2.08 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CLSD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.